Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry.
Tubach, F. 1; Salmon, D. 2; Ravaud, P. 1; Allanore, Y. 3; Goupille, P. 4; Breban, M. 5; Pallot-Prades, B. 6; Pouplin, S. 7; Sacchi, A. 8; Chichemanian, R. M. 9; Bretagne, S. 10; Emilie, D. 11; Lemann, M. 12; Lorthololary, O. 13; Mariette, X. 14,*; Research Axed on Tolerance of Biotherapies Group
Arthritis & Rheumatism.
60(7):1884-1894, July 2009.
(Format: HTML, PDF)